Free Trial

Agios Pharmaceuticals Q2 2023 Earnings Report

Agios Pharmaceuticals logo
$41.86 -0.10 (-0.24%)
(As of 09:39 AM ET)

Agios Pharmaceuticals EPS Results

Actual EPS
-$1.51
Consensus EPS
-$1.60
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$1.68

Agios Pharmaceuticals Revenue Results

Actual Revenue
$6.70 million
Expected Revenue
$6.46 million
Beat/Miss
Beat by +$240.00 thousand
YoY Revenue Growth
+20.10%

Agios Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
Before Market Opens

Conference Call Resources

"X-Ray Vision" could find thousands of hidden market opportunities (Ad)

Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.

Just tap here to join the presentation.

Agios Pharmaceuticals Earnings Headlines

Q1 EPS Forecast for Agios Pharmaceuticals Lowered by Analyst
Vacuum up cash with these special trades?
Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.
See More Agios Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agios Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agios Pharmaceuticals and other key companies, straight to your email.

About Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO), a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

View Agios Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings